Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts:
Part 1: Single dose of VMX-C001 or placebo in healthy volunteers.
Part 2: Single dose of VMX-C001 or placebo in combination with a selected factor 10a (FXa) direct oral anticoagulant (DOAC) in healthy older subjects.